Your browser is no longer supported. Please, upgrade your browser.
Settings
EGRX Eagle Pharmaceuticals, Inc. daily Stock Chart
EGRX [NASD]
Eagle Pharmaceuticals, Inc.
Index- P/E10.48 EPS (ttm)6.21 Insider Own0.30% Shs Outstand14.94M Perf Week5.42%
Market Cap971.40M Forward P/E14.01 EPS next Y4.64 Insider Trans0.00% Shs Float13.14M Perf Month6.71%
Income100.20M PEG0.70 EPS next Q1.00 Inst Own- Short Float22.91% Perf Quarter14.37%
Sales271.10M P/S3.58 EPS this Y-12.70% Inst Trans0.21% Short Ratio13.56 Perf Half Y19.13%
Book/sh11.37 P/B5.72 EPS next Y7.16% ROA43.30% Target Price63.67 Perf Year-9.96%
Cash/sh6.53 P/C9.96 EPS next 5Y15.00% ROE61.20% 52W Range45.05 - 97.15 Perf YTD21.71%
Dividend- P/FCF13.62 EPS past 5Y58.40% ROI53.80% 52W High-33.07% Beta1.09
Dividend %- Quick Ratio5.20 Sales past 5Y81.90% Gross Margin77.00% 52W Low44.33% ATR2.68
Employees77 Current Ratio5.30 Sales Q/Q66.70% Oper. Margin33.90% RSI (14)63.77 Volatility4.01% 4.84%
OptionableYes Debt/Eq0.29 EPS Q/Q34.70% Profit Margin37.00% Rel Volume1.13 Prev Close63.45
ShortableYes LT Debt/Eq0.26 EarningsFeb 28 BMO Payout0.00% Avg Volume222.09K Price65.02
Recom2.30 SMA208.00% SMA5010.73% SMA2004.28% Volume249,779 Change2.47%
Nov-09-17Reiterated RBC Capital Mkts Outperform $81 → $75
Sep-06-17Reiterated Mizuho Underperform $40 → $37
Jul-27-17Reiterated RBC Capital Mkts Outperform $94 → $81
Jul-27-17Reiterated Mizuho Underperform $57 → $40
May-09-17Reiterated RBC Capital Mkts Outperform $86 → $94
Jan-09-17Downgrade Mizuho Neutral → Underperform $78 → $64
Nov-16-16Downgrade Mizuho Buy → Neutral $78
Nov-03-16Upgrade Mizuho Neutral → Buy $62 → $78
Nov-03-16Reiterated RBC Capital Mkts Outperform $80 → $93
Oct-26-16Reiterated Mizuho Buy $65 → $62
Aug-16-16Reiterated Mizuho Neutral $47 → $65
Jun-20-16Downgrade Mizuho Buy → Neutral $66 → $47
May-10-16Reiterated RBC Capital Mkts Outperform $94 → $78
Mar-18-16Reiterated Mizuho Buy $81 → $71
Feb-26-16Reiterated Mizuho Buy $112 → $81
Dec-09-15Initiated Mizuho Buy $112
Jul-29-15Reiterated Piper Jaffray Overweight $94 → $119
Jul-06-15Reiterated Piper Jaffray Overweight $75 → $94
Jun-16-15Reiterated Cantor Fitzgerald Buy $65 → $95
Apr-20-15Reiterated Piper Jaffray Overweight $55 → $75
Feb-15-18 04:30PM  Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Year End 2017 Financial Results on February 26, 2018 Business Wire +5.14%
Feb-12-18 04:30PM  Eagle Pharmaceuticals, Inc. to Present at 2018 RBC Capital Markets Global Healthcare Conference Business Wire
Feb-07-18 07:30AM  Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX Business Wire
Jan-02-18 08:07AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit +8.97%
06:50AM  Eagle Pharmaceuticals, Inc. to Present at 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-28-17 12:04PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:47AM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-21-17 07:14AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : December 21, 2017 Capital Cube
Dec-19-17 08:00AM  Research Report Identifies 2U, AK Steel Holding, American Water Works, Urban Edge Properties, Guidewire Software, and Eagle Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Dec-15-17 07:13PM  Cramer's lightning round: Buy Cisco when it goes below $3... CNBC Videos
Dec-07-17 06:50AM  Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant Business Wire
Nov-27-17 08:05AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit
Nov-20-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at 29th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-16-17 09:01PM  Barron's After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals Plunges Barrons.com
08:36PM  Edited Transcript of EGRX earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-15-17 08:06AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit
Nov-10-17 01:10PM  Eagle Pharmaceuticals, Inc. Value Analysis (NASDAQ:EGRX) : November 10, 2017 Capital Cube
Nov-09-17 07:21AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : November 9, 2017 Capital Cube -7.21%
Nov-08-17 10:44AM  Eagle Pharmaceuticals posts 3Q profit Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results Business Wire
06:10AM  Eagle Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-07-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Jefferies 2017 London Healthcare Conference Business Wire
Oct-30-17 04:30PM  Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017 Business Wire -6.52%
Oct-27-17 04:44PM  Eagle Pharma gets tentative FDA approval for Lilly's Alimta version Reuters
03:14PM  FDA tentatively approves Eagle Pharma's cancer drug Reuters
03:02PM  Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute Business Wire
Oct-24-17 09:37AM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 24, 2017 Capital Cube
Oct-17-17 07:33AM  Eagle Pharmaceuticals Announces New Patent for RYANODEX Business Wire
Oct-15-17 12:00PM  3 Biotech Values in a Fully Valued Market TheStreet.com
Oct-13-17 10:44AM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 13, 2017 Capital Cube
Oct-11-17 08:23AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : October 11, 2017 Capital Cube
Oct-02-17 10:49AM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 2, 2017 Capital Cube
Sep-28-17 04:21PM  Edited Transcript of EGRX earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Sep-25-17 08:52AM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017 Capital Cube
Sep-22-17 07:40AM  Corporate News Blog - Eagle Pharmas Licenses Japanese Rights to SymBio Pharma for Bendamustine HCl Ready-to-dilute and Rapid Infusion Injection Products ACCESSWIRE
Sep-20-17 06:50AM  Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited Business Wire
Sep-19-17 11:08PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : September 20, 2017 Capital Cube
07:57PM  Eagle Pharmaceuticals, Inc. Value Analysis (NASDAQ:EGRX) : September 19, 2017 Capital Cube
Sep-18-17 09:25AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : September 18, 2017 Capital Cube
Sep-06-17 06:50AM  Eagle Pharmaceuticals, Inc. to Present at September Investor Conferences Business Wire
Sep-05-17 10:00AM  Eagle Pharmaceuticals Announces Positive Results of Study Conducted to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure Business Wire
Aug-22-17 08:01AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit
Aug-14-17 03:15PM  Eagle Pharmaceuticals, Inc.: Sudden move in price, will it continue? Capital Cube
Aug-11-17 08:05AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit +11.12%
Aug-10-17 08:06AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit
Aug-09-17 10:25PM  Eagle Pharmaceuticals posts 2Q profit Associated Press +5.09%
06:50AM  Eagle Pharmaceuticals, Inc. Reports Second Quarter 2017 Results Business Wire
Aug-03-17 08:12PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : August 4, 2017 Capital Cube
Jul-31-17 06:50AM  Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2017 Financial Results on August 9, 2017 Business Wire
Jul-26-17 03:11PM  Mizuho Top Analyst Buzzes Mayday as Eagle Pharmaceuticals Inc (EGRX) Valuation Likely to Collapse SmarterAnalyst -23.80%
02:27PM  FDA rejects Eagle Pharmaceuticals' heat stroke treatment Reuters
02:27PM  FDA rejects Eagle Pharmaceuticals' heat stroke treatment Reuters
01:02PM  UPDATE: Eagle Pharma stock plummets 21% on news that heat stroke drug failed to get FDA approval MarketWatch
12:30PM  Eagle Pharmaceuticals Receives Complete Response Letter from FDA on RYANODEX for Exertional Heat Stroke Application Business Wire
Jul-25-17 09:19AM  Eagle Pharmaceuticals, Inc. Issues Statement Regarding RYANODEX Application PDUFA Date for Exertional Heat Stroke Business Wire
Jul-24-17 03:38PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : July 24, 2017 Capital Cube
Jul-20-17 01:30PM  3 Stocks the Smartest Investors Are Buying Right Now Motley Fool
Jul-14-17 02:10PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : July 14, 2017 Capital Cube
Jul-11-17 09:18AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : July 11, 2017 Capital Cube
Jul-03-17 08:13AM  Key FDA Events to Watch Out for in Jul 2017 Zacks
Jun-26-17 08:39AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : June 26, 2017 Capital Cube
Jun-25-17 09:42AM  These 3 Stocks Are Up Over 500% in the Last 3 Years Motley Fool
Jun-19-17 03:14PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : June 19, 2017 Capital Cube
Jun-16-17 02:34PM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Capital Cube
Jun-08-17 08:56AM  What Falling Estimates & Price Mean for Eagle Pharmaceuticals (EGRX) Zacks
May-31-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June Business Wire
May-25-17 04:10PM  Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts Investor's Business Daily
01:38PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
May-16-17 08:16AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : May 16, 2017 Capital Cube
May-15-17 06:50AM  Eagle Pharmaceuticals Appoints Pete A. Meyers as Chief Financial Officer Business Wire -13.60%
May-12-17 01:00PM  Edited Transcript of EGRX earnings conference call or presentation 8-May-17 12:30pm GMT Thomson Reuters StreetEvents
11:56AM  Edited Transcript of EGRX earnings conference call or presentation 8-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-10-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2017 Health Care Conference Business Wire +8.71%
May-08-17 06:56AM  Eagle Pharmaceuticals posts 1Q profit Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports First Quarter 2017 Results Business Wire
Apr-25-17 07:00AM  Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2017 Financial Results on May 8, 2017 Business Wire
Apr-24-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at 42nd Annual Deutsche Bank Health Care Conference Business Wire
02:26PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : April 24, 2017 Capital Cube
Apr-07-17 08:33AM  15 companies with outsized sales growth and widening profit margins MarketWatch
Apr-05-17 04:43PM  15 companies with outsized sales growth and widening profit margins
Mar-27-17 06:50AM  FDA Grants Priority Review for Eagle Pharmaceuticals Ryanodex NDA for the Treatment of Exertional Heat Stroke Business Wire
Mar-26-17 06:43AM  3 Top Biotech Stocks to Buy in 2017 Motley Fool
Mar-24-17 01:23PM  Director of Eagle Pharmaceuticals Buys Shares
Mar-21-17 01:04PM  EAGLE PHARMACEUTICALS, INC. Financials -7.11%
10:24AM  Eagle Pharma Cancer Drug Secures New Patents Investopedia
08:00AM  Eagle Pharmaceuticals Announces Three New Patents Issued for Bendeka Business Wire
Mar-16-17 07:11AM  EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,
07:00AM  Eagle Pharmaceuticals Appoints Richard A. Edlin to Board of Directors Business Wire
Mar-15-17 05:25PM  EAGLE PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-06-17 10:10AM  New Strong Sell Stocks for March 6th Zacks
Mar-03-17 11:59AM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017 Capital Cube
Mar-02-17 01:37PM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017
Mar-01-17 04:36PM  Edited Transcript of EGRX earnings conference call or presentation 1-Mar-17 1:30pm GMT Thomson Reuters StreetEvents
07:07AM  Q4 2016 Eagle Pharmaceuticals Inc Earnings Release - Before Market Open
07:04AM  Eagle Pharmaceuticals posts 4Q profit Associated Press
06:57AM  EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
06:50AM  Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results Business Wire
Feb-28-17 09:01AM  Eagle Pharmaceuticals Pemetrexed NDA Accepted for Filing by the FDA Business Wire
08:26AM  MedTech Stocks' Q4 Earnings on Mar 1: ICUI, GKOS & EGRX
07:55AM  Eagle Pharmaceuticals Announces 11th Patent Issued for Bendeka Business Wire
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RATOFF STEVEN BDirectorDec 18Option Exercise0.902,3402,10615,664Dec 20 05:54 PM
Meyers Pete A.Chief Financial OfficerAug 16Buy55.4535019,406700Aug 16 08:30 PM
Braunstein Douglas LDirectorAug 09Buy49.0720,4001,001,087971,000Aug 11 04:34 PM
Meyers Pete A.Chief Financial OfficerJun 12Buy71.4935025,021350Jun 12 04:46 PM
Pernock DavidPres. & Chief Comm. OfficerMay 19Buy79.6925520,321966May 19 04:42 PM
Pernock DavidPres. & Chief Comm. OfficerMay 16Buy82.2420016,448711May 16 05:37 PM
ProQuest Investments IV, L.P.10% OwnerApr 25Option Exercise34.1954,1801,852,67760,957Apr 27 04:19 PM
ProQuest Investments IV, L.P.10% OwnerApr 25Sale88.3854,1804,788,4826,777Apr 27 04:19 PM
ProQuest Investments IV, L.P.10% OwnerApr 03Sale83.1361,4205,105,8453,584,087Apr 03 05:22 PM
ProQuest Investments IV, L.P.10% OwnerMar 31Sale83.0223,6891,966,6613,645,507Apr 03 05:22 PM
ProQuest Investments IV, L.P.10% OwnerMar 30Sale83.006,223516,5093,669,196Apr 03 05:22 PM
ProQuest Investments IV, L.P.10% OwnerMar 29Sale83.0160,8555,051,5746,777Mar 29 05:34 PM
ProQuest Investments IV, L.P.10% OwnerMar 28Sale83.026,182513,2303,734,174Mar 29 05:34 PM
ProQuest Investments IV, L.P.10% OwnerMar 27Sale83.0039,4313,272,7737,277Mar 29 05:34 PM
Krill Steven L.EVP & Chief Scientific OfficerMar 23Option Exercise12.647,02588,8077,025Mar 24 04:41 PM
Krill Steven L.EVP & Chief Scientific OfficerMar 23Sale82.067,025576,4890Mar 24 04:41 PM
ProQuest Investments IV, L.P.10% OwnerMar 23Sale83.0170058,1073,778,087Mar 23 05:02 PM
Krill Steven L.EVP & Chief Scientific OfficerMar 22Option Exercise6.837,10048,5177,100Mar 24 04:41 PM
Edlin Richard A.DirectorMar 22Buy79.446,000476,64029,400Mar 22 04:47 PM
Krill Steven L.EVP & Chief Scientific OfficerMar 22Sale80.097,100568,6410Mar 24 04:41 PM
Pernock DavidPres. & Chief Comm. OfficerMar 21Buy83.98615,123511Mar 21 04:37 PM
ProQuest Investments IV, L.P.10% OwnerMar 21Sale83.1050041,5503,778,787Mar 23 05:02 PM
ProQuest Investments IV, L.P.10% OwnerMar 20Sale82.1051,8834,259,5943,779,287Mar 20 05:40 PM
ProQuest Investments IV, L.P.10% OwnerMar 17Sale82.0138,9973,198,1443,831,170Mar 20 05:40 PM
ProQuest Investments IV, L.P.10% OwnerMar 16Sale82.089,120748,5703,870,167Mar 20 05:40 PM
Pernock DavidPres. & Chief Comm. OfficerMar 09Buy77.8445035,028450Mar 10 07:20 PM